01—Abstract
Summary
Summary of the 10-K filed March 30, 2000. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. reported a net loss of $16.8 milliona, or $0.88 per share, for the fiscal year ended December 31, 1999, compared with a net loss of $20.0 million, or $1.10 per share, in 1998 and net income of $5.1 million, or $0.30 per share, in 1997.
Total revenues were $16.8 millionb in 1999 versus $16.0 million in 1998, while research and development expenses rose to $29.2 million from $21.8 million and general and administrative expenses rose to $7.5 million from $6.6 million. The company has no approved products and states that all of its product candidates are at an early stage of development, with revenues expected to come from strategic alliances. The company's pipeline spans five clinical programs: a CRF receptor antagonist partnered with Janssen for anxiety/depression (Phase II), NBI-34060 for insomnia (Phase II, with a 228-subject transient insomnia study completed), the IL-4 Fusion Toxin NBI-3001 for glioblastoma (Phase I/II, with FDA Fast Track Designation granted in October 1999), an altered peptide ligand for multiple sclerosis (Phase II, reacquired from Novartis on January 7, 2000), and an altered peptide ligand for Type I diabetes (Phase I).
The company closed a private placement of 2.3 million shares at $18.00c per share in December 1999, with net proceeds of $39.3 million. Cash, cash equivalents and short-term investments totaled $91.1 million at year-end, and management states that existing resources are sufficient through 2003, though it expects similar operating losses over the next two to three years.
Key risks highlighted in the filing include dependence on strategic partners, reliance on third-party contract manufacturers, intense competition from better-capitalized companies, uncertainty in clinical and regulatory outcomes, and the possibility of additional dilutive financing. The filing also notes that the Taisho agreement for the diabetes APL is an option that Taisho may or may not exercise, and that the company sold its interest in Neuroscience Pharma Inc. in December 1999.
02—Key points
Key Highlights
- Net loss narrowed to $16.8 million ($0.88 per share) in 1999 from $20.0 million ($1.10 per share) in 1998, though revenues were roughly flat at $16.8 million versus $16.0 million.
- Research and development expenses increased to $29.2 million from $21.8 million, reflecting advancement of drug candidates through clinical phases.
- Five clinical programs: CRF antagonist (Phase II, with Janssen), NBI-34060 for insomnia (Phase II), IL-4 Fusion Toxin for glioblastoma (Phase I/II), APL for multiple sclerosis (Phase II), and APL for Type I diabetes (Phase I).
- The IL-4 Fusion Toxin received FDA Fast Track Designation in October 1999.
- A December 1999 private placement of 2.3 million shares at $18.00 per share yielded net proceeds of $39.3 million.
- Cash, cash equivalents and short-term investments were $91.1 million at December 31, 1999, versus $62.7 million a year earlier; the company expects these resources to be sufficient through 2003.
- Novartis terminated its multiple sclerosis collaboration effective January 2000, and Neurocrine reacquired the program rights on January 7, 2000.
03—Questions
Frequently Asked Questions
Is Neurocrine Biosciences generating product revenue?
No. The filing states that the company has not generated any revenues from product sales and does not expect product revenues in the foreseeable future. Its revenues come from sponsored research, milestones and license fees under strategic alliances.
How much cash does the company have and how long will it last?
Cash, cash equivalents and short-term investments totaled $91.1 million at December 31, 1999. The company believes these resources, together with interest income and future alliance payments, will be sufficient through 2003, but notes that additional funding may be needed and that equity financing would be dilutive.
What is the status of the most advanced programs?
The CRF receptor antagonist, partnered with Janssen, is in Phase II for anxiety and depression. NBI-34060 for insomnia completed a Phase II transient insomnia study in 228 subjects, with chronic insomnia dose evaluation planned for 2000. The IL-4 Fusion Toxin is in a Phase I/II glioblastoma trial, with enrollment expected to complete in early 2000.
What are the main risks to investors?
The filing cites early-stage development, dependence on corporate partners that can terminate or deprioritize their agreements, reliance on third-party manufacturers, strong competition from larger companies, uncertain FDA approval, patent and proprietary-rights uncertainty, and a stock price that the filing describes as highly volatile.
What happened with the multiple sclerosis program and the diabetes program?
Novartis exercised its right to terminate the multiple sclerosis collaboration effective January 7, 2000, and Neurocrine reacquired the worldwide rights and began data analysis. For the Type I diabetes APL (NBI-6024), Neurocrine granted Taisho Pharmaceutical an exclusive option to obtain European and Asian rights, which Taisho has not yet exercised; Neurocrine retains North American rights.
04—Continue